An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells
Alexandre Nicolas, Gérémy Sannier, Mathieu Dubé, Manon Nayrac, Alexandra Tauzin, Mark M. Painter, Rishi R. Goel, Mélanie Laporte, Gabrielle Gendron‐Lepage, Halima Medjahed, Justine C. Williams, Nathalie Brassard, Julia Niessl, Laurie Gokool, Chantal Morrisseau, Pascale Arlotto, Cécile Tremblay, Valérie Martel‐Laferrière, Andrés Finzi, Allison R. Greenplate, E. John Wherry, Daniel E. Kaufmann
Abstract
A 16-week interval increases B cell response and maturity compared to a 3-week delay A 16-week interval has limited impact on the magnitude of CD4 and CD8 T cell responses A long interval is associated with an early increase of specific SARS-CoV-2 cTfh T cell phenotypes in 16-week versus 3-week regimens converge at late time points
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Immunity2019-20 coronavirus outbreakPrime (order theory)VirologyImmunologyBiologyChemistryMedicineImmune systemMathematicsInfectious disease (medical specialty)CombinatoricsDiseaseInternal medicineOutbreakSARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers